
Kimberly-Clark (KMB) Stock Forecast & Price Target
Kimberly-Clark (KMB) Analyst Ratings
Bulls say
Kimberly-Clark is a dominant force in the tissue and hygiene market, with over 50% of its sales derived from personal care products and approximately one-third from consumer tissue goods. The company is actively enhancing its innovation pipeline, which is expected to be more robust in 2026, allowing it to leverage new technologies across its product offerings. Additionally, Kimberly-Clark plans to integrate Kenvue's consumer health portfolio into its operations by the second half of 2026, potentially expanding its market reach and enhancing revenue streams.
Bears say
Kimberly-Clark has experienced a significant downward revision of its 3Q25 North America organic sales growth estimate, shifting from a prior increase of 4.5% to a decline of 4.0%. Additionally, trends indicate a troubling -2.7% decline in US measured retail sales for the third quarter of 2025. Furthermore, earnings per share (EPS) projections have been decreased, with the fiscal 2025 estimate reduced from $7.60 to $7.41, and the 2026 EPS forecast lowered from $8.00 to $7.85.
This aggregate rating is based on analysts' research of Kimberly-Clark and is not a guaranteed prediction by Public.com or investment advice.
Kimberly-Clark (KMB) Analyst Forecast & Price Prediction
Start investing in Kimberly-Clark (KMB)
Order type
Buy in
Order amount
Est. shares
0 shares